ArticleACS pharmacology & translational science2022

Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.

Piyusha P Pagare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.